Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-25 @ 2:16 AM
Ignite Modification Date:
2025-12-25 @ 2:16 AM
NCT ID:
NCT00132860
Brief Summary:
The purpose of the study is to investigate, in patients with moderate to severe chronic obstructive lung disease, whether intermittent antibiotic treatment leads to:
* A slower rate of decline in forced expiratory volume in one second (FEV1);
* A reduction in the frequency and severity of exacerbations;
* Fewer hospital admissions for chronic obstructive pulmonary disease (COPD);
* Lower mortality;
* An improved quality of life as compared to a group of placebo treated patients.
Detailed Description:
Study Population: Patients with moderate to severe chronic obstructive lung disease.
Trial Phase: IV
Study Design: Prospective, randomised, double-blind, placebo- controlled clinical trial.
Study Medicine: Azithromycin.
Drug Administration: Oral.
Drug Dose: 500 mg once daily for 3 days every month.
Duration of Treatment: 3 years
Number of Evaluable Patients: 200 per treatment arm
Number of Included Patients: 400 per treatment arm, 800 patients in total.
Study:
NCT00132860
Study Brief:
Protocol Section:
NCT00132860